Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply

Reuters

2025/12/18

Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply

Kamada Ltd. has announced that it has been awarded a two-year extension of an existing supply tender from Canadian Blood Services (CBS) for four specialty plasma-derived products: WINRHO®, HEPAGAM®, CYTOGAM®, and VARIZIG®. The extension is valued at $10-$14 million and will secure ongoing sales of approximately $5.0-$7.0 million per year between the second quarter of 2026 and the first quarter of 2028. All four products are approved by Health Canada and the U.S. Food and Drug Administration. Kamada also continues to supply its KAMRAB® anti-Rabies Immunoglobulin product and GLASSIA® AAT product in Canada. The company has reiterated its 2025 full-year revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, and projects double-digit growth in revenues and profitability in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-123054), on December 18, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2592084759"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592084759\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592084759?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592084759","market":"us","top_or_hot":-1,"title":"Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KMDA\">Kamada Ltd.</a> has announced that it has been awarded a two-year extension of an existing supply tender from Canadian Blood Services (CBS) for four specialty plasma-derived products: WINRHO®, HEPAGAM®, CYTOGAM®, and VARIZIG®. The extension is valued at $10-$14 million and will secure ongoing sales of approximately $5.0-$7.0 million per year between the second quarter of 2026 and the first quarter of 2028. All four products are approved by Health Canada and the U.S. Food and Drug Administration. Kamada also continues to supply its KAMRAB® anti-Rabies Immunoglobulin product and GLASSIA® AAT product in Canada. The company has reiterated its 2025 full-year revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, and projects double-digit growth in revenues and profitability in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-123054), on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-18 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KMDA\">Kamada Ltd.</a> has announced that it has been awarded a two-year extension of an existing supply tender from Canadian Blood Services (CBS) for four specialty plasma-derived products: WINRHO®, HEPAGAM®, CYTOGAM®, and VARIZIG®. The extension is valued at $10-$14 million and will secure ongoing sales of approximately $5.0-$7.0 million per year between the second quarter of 2026 and the first quarter of 2028. All four products are approved by Health Canada and the U.S. Food and Drug Administration. Kamada also continues to supply its KAMRAB® anti-Rabies Immunoglobulin product and GLASSIA® AAT product in Canada. The company has reiterated its 2025 full-year revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, and projects double-digit growth in revenues and profitability in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-123054), on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL5q1jVJ:1","article_id":"2592084759","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592084759","pubTimestamp":1766059285,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kamada Ltd. has announced that it has been awarded a two-year extension of an existing supply tender from Canadian Blood Services  for four specialty plasma-derived products: WINRHO, HEPAGAM, CYTOGAM, and VARIZIG. The extension is valued at $10-$14 million and will secure ongoing sales of approximately $5.0-$7.0 million per year between the second quarter of 2026 and the first quarter of 2028. All four products are approved by Health Canada and the U.S. Food and Drug Administration. Kamada also continues to supply its KAMRAB anti-Rabies Immunoglobulin product and GLASSIA AAT product in Canada. The company has reiterated its 2025 full-year revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, and projects double-digit growth in revenues and profitability in 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KMDA":"Kamada Ltd."},"translate_title":"Kamada获得加拿大血浆衍生产品供应延期10-1400万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KMDA":0.9},"content_text":"Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply\n    \n\nKamada Ltd. has announced that it has been awarded a two-year extension of an existing supply tender from Canadian Blood Services (CBS) for four specialty plasma-derived products: WINRHO®, HEPAGAM®, CYTOGAM®, and VARIZIG®. The extension is valued at $10-$14 million and will secure ongoing sales of approximately $5.0-$7.0 million per year between the second quarter of 2026 and the first quarter of 2028. All four products are approved by Health Canada and the U.S. Food and Drug Administration. Kamada also continues to supply its KAMRAB® anti-Rabies Immunoglobulin product and GLASSIA® AAT product in Canada. The company has reiterated its 2025 full-year revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, and projects double-digit growth in revenues and profitability in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-123054), on December 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}